Hjem › Myelofibrose › Tennessee
Kliniske studier for Myelofibrose i Tennessee
9 studier for Myelofibrose søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Tri-Star Centennial Medical Center, Nashville
- Vanderbilt University, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04176198A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tristar BMT, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Vanderbilt-Ingram Cancer Center (VICC)-Nashville, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Vanderbilt University/Ingram Cancer Center, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06661915Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Tristar Bmt/Tcto, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT07441694Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. apr. 2026 · NCT06517875A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. apr. 2026 · NCT06034002SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Tennessee Oncology, Chattanooga
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2025 · NCT06479135Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.